Efficacy and Safety on Prouk for STEMI Patients in China

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT02367976

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Suzhou RxD Biopharmaceutical Co., Ltd (from the registry)
Registry
  • NCT NCT02367976
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02367976. Randomized; single masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety on Prouk for STEMI Patients in China
Condition
STEMI
Intervention (Drug)
rhprouk
Lead sponsor
Suzhou RxD Biopharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02367976
Content hash
223e106cd06c35c65bef912222a9bfeca79da1da228bcd47a4016a63ac0294e6